Okami Medical announces first patients treated with Lobo vascular occluder

3857
Lobo vascular occlusion okami
LOBO vascular occlusion system (Okami Medical)

Okami Medical has announced the successful completion of the first cases with the Lobo vascular occlusion system. The first offering in the company’s product portfolio, Lobo-3, recently received 510(k) clearance from the US Food and Drug Administration (FDA) for the occlusion of peripheral arteries.

The Lobo (Low-profile braided occluder) system is uniquely designed to provide interventional physicians with a single-device, one-and-done solution for the occlusion of various arterial targets without the need for multiple embolic devices. The Lobo system combines a patented design with proprietary Hdbraid technology to create a highly occlusive pore structure that substantially reduces blood flow and accelerates vessel closure. The Lobo-3 occluder is intended for use in 1.5–3mm diameter vessels.

Ripal Gandhi, interventional radiologist, Miami Cardiac and Vascular Institute, performed the first Lobo-3 implant. “We have successfully utilised the Lobo-3 occluder to embolise several small vessels via a microcatheter. The device has resulted in immediate occlusion of the target vessels. The device tracks well and deploys precisely at the desired location.  The Lobo-3 occluder is a great addition to the embolic armamentarium for the occlusion of small vessels,” said Gandhi.

“Guided by world-class physician collaborators, Okami is committed to addressing numerous challenging aspects of peripheral vascular occlusion,” said Bob Rosenbluth, president and CEO of Okami Medical. “We are very pleased with the clinical performance of the Lobo-3 occluder in the initial cases. The device is in clinical use at key centres and we look forward to expanding our launch in 2020.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here